Bleeding
Ticagrelor monotherapy reduces bleeding risk after PCI regardless of DES platform
Dabigatran with P-glycoprotein inhibitors may increase bleeding risk in AF, normal kidney function
In ACS, nearly 8% of bleeding events linked to new cancer diagnosis
Oral anticoagulation alone reduces bleeding after TAVR vs. dual therapy

The incidence of serious bleeding after transcatheter aortic valve replacement was lower in patients assigned oral anticoagulation alone compared with those assigned oral anticoagulation and clopidogrel, according to data from the POPULAR-TAVI trial presented at the American College of Cardiology Scientific Session.
Dual therapy may confer less major bleeding vs. triple therapy in AF, PCI
Apixaban may confer less stroke, systemic embolism, bleeding vs. rivaroxaban
Physicians inappropriately favor discontinuing PPIs in high risk upper GI bleeding cases
GI bleeding may increase cancer risk in AF with anticoagulation
Post-PCI ticagrelor does not lower MACE risk vs. clopidogrel in cohort study

Among patients with ACS who underwent PCI and received an outpatient prescription for ticagrelor or clopidogrel, ticagrelor was not associated with a significant reduction in risk for MACE, and those who received ticagrelor had more major bleeding and dyspnea, according to data from a population-based cohort study published in JAMA Internal Medicine.